DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Baselga J, Bradbury I, Eidtmann H et al.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a
randomised, open-label, multicentre, phase 3 trial.
Lancet 2012;
379: 633-640
We do not assume any responsibility for the contents of the web pages of other providers.